Heroin Drug Test: Detection Times Explained

A heroin drug test detects the metabolites that heroin breaks down into after it enters the body, not the drug itself. Because heroin converts to 6-monoacetylmorphine (6-MAM) and then morphine within minutes of use, most standard opiate panels identify heroin use by flagging those metabolites rather than diacetylmorphine directly. How long those metabolites remain detectable depends on the test type, frequency of use, and individual metabolism.

Detection windows vary significantly across urine, blood, saliva, and hair testing, which is why understanding each format matters for anyone navigating employment screening, legal proceedings, or clinical monitoring.

Key Takeaways

• Heroin converts to 6-monoacetylmorphine (6-MAM) within minutes, making 6-MAM the only metabolite that confirms heroin use specifically over morphine or codeine. 6-MAM clears urine within 2 to 8 hours, per Cone et al. (1991) in the Journal of Analytical Toxicology.
• Urine drug screens detect heroin metabolites for 2 to 4 days in single-use cases and up to 7 days in heavy or chronic use, per Mayo Clinic Proceedings clinical guidance.
• Hair follicle testing produces the longest detection window at up to 90 days for scalp hair, making it the standard for pre-employment and pattern-of-use testing.
• Standard immunoassay panels classify heroin as an opiate, not as “heroin” by name. Confirmatory gas chromatography-mass spectrometry (GC-MS) testing is required to distinguish heroin from morphine or codeine on a positive screen.
• In New Jersey, in 2023 opioid use disorder drove the majority of the state’s 3,341 overdose deaths, per the New Jersey Department of Health. Effective evidence-based outpatient treatment is available for individuals ready to address heroin dependence after testing positive.

What a Heroin Drug Test Actually Detects

Heroin drug testing does not identify the molecule diacetylmorphine itself in most clinical settings because the compound metabolizes too rapidly for routine detection. Standard drug screens target the metabolic byproducts that heroin produces after hepatic first-pass metabolism processes it through the liver and bloodstream.

The Metabolite Pathway: From Diacetylmorphine to Morphine

After administration, diacetylmorphine undergoes rapid deacetylation to produce three primary metabolites in sequence. Each metabolite carries a different detection window and clinical significance.

• Diacetylmorphine (heroin itself): The parent compound is detectable in blood for only 3 to 5 minutes after administration before converting to 6-MAM, per Mayo Clinic Proceedings clinical review data.
• 6-Monoacetylmorphine (6-MAM): The first and most diagnostically important metabolite. 6-MAM is unique to heroin and does not appear after morphine or codeine use, making it the confirmatory biomarker for heroin use. Its half-life in urine averages 36 minutes, with a detectable window of 2 to 8 hours post-use.
• Morphine: The terminal metabolite. Morphine remains detectable in urine for 2 to 4 days after heroin use and is the primary target of standard opiate immunoassay panels. Because morphine also derives from morphine sulfate prescriptions and codeine metabolism, a morphine-positive result alone does not confirm heroin use.
• Morphine glucuronides (M3G and M6G): Conjugated morphine metabolites produced during hepatic processing. Morphine-3-glucuronide accounts for approximately 70% of morphine excretion within 48 hours. These glucuronides extend the overall metabolite detection window in urine.

How Standard Opiate Panels Classify Heroin

A standard 5-panel or 10-panel immunoassay drug test classifies heroin under the “opiates” category. The screen does not produce a result labeled “heroin positive.” Instead, the panel detects morphine at or above the SAMHSA standard cutoff threshold of 2,000 ng/mL for federally regulated testing, with many clinical and workplace panels using a lower 300 ng/mL screening cutoff.

The Clinical Opiate Withdrawal Scale (COWS) is the validated clinical assessment tool used by addiction medicine providers to measure opioid withdrawal severity across 11 physiological and behavioral signs. A COWS score above 12 indicates moderate withdrawal and typically precedes pharmacological treatment decisions, including buprenorphine induction after a failed heroin drug test confirms active use.

Why Heroin Stays in Your Body (and for How Long)

The duration heroin metabolites remain detectable is governed by the pharmacokinetics of opioid metabolism, particularly the rate at which the liver converts morphine to glucuronide conjugates and the kidneys excrete those conjugates into urine.

Mu-Opioid Receptor Binding and Clearance Mechanisms

Heroin binds to mu-opioid receptors (MOR) in the central nervous system with higher affinity than morphine, producing its characteristic euphoria and respiratory depression. After MOR binding, the body clears heroin metabolites through renal excretion, with the kidneys filtering morphine glucuronides into urine over 24 to 96 hours depending on hydration status and renal function.

Individual Metabolism Factors That Drive Detection Length

Metabolic rate is the primary determinant of how long a heroin drug test will return a positive result for any individual. Several physiological and behavioral factors lengthen or shorten the detection window.

• Frequency and dose of use: A single heroin use produces morphine detectable for 2 to 3 days in most adults. Chronic daily use saturates hepatic metabolism pathways, extending urinary morphine excretion to 5 to 7 days as the liver processes accumulated metabolite stores.
• Route of administration: Intravenous heroin produces peak blood 6-MAM levels within seconds and maximizes metabolite load. Smoked or insufflated heroin delivers lower peak concentrations, potentially shortening the urine detection window by 12 to 24 hours in light users.
• Liver and kidney function: Impaired hepatic metabolism from cirrhosis, hepatitis C co-infection, or alcohol-related liver disease slows glucuronide conjugation, extending morphine’s presence in urine. Reduced creatinine clearance from kidney dysfunction similarly delays urinary excretion.
• Body mass and fat distribution: Morphine and its glucuronide metabolites are primarily water-soluble and do not accumulate in fat tissue the way cannabinoids do. Higher body mass correlates with greater total blood volume, diluting metabolite concentration and occasionally reducing detection sensitivity near threshold levels.
• Hydration level: High fluid intake dilutes urine creatinine and metabolite concentration. Urine creatinine below 20 mg/dL signals specimen dilution, which prompts laboratories to flag the sample as potentially adulterated or substituted rather than genuinely negative.

Researcher Reference: Lofwall and Walsh on Opioid Metabolite Windows

Lofwall and Walsh (2014) documented in Substance Abuse that urine detection windows for heroin metabolites are highly variable across individuals and are best interpreted alongside clinical presentation rather than as standalone evidence of recency or quantity of use. Their research reinforced that a negative urine morphine result does not exclude recent heroin use if the specimen was collected beyond the 2- to 4-day detection window, and that hair or blood drug testing may be required for accurate timeline reconstruction.

Heroin Drug Test Detection Times by Test Type

Each test matrix captures heroin metabolites over a different timeframe, choosing the test type critical for the screen, whether that is recent-use detection, long-term pattern assessment, or forensic confirmation.

Detection Time Comparison Table

Test Type	What It Detects	Detection Window	Cutoff Threshold	Primary Use Case
Urine (immunoassay)	Morphine, morphine glucuronides	2 to 4 days (single use); up to 7 days (chronic use)	300 or 2,000 ng/mL (morphine)	Workplace, clinical monitoring, probation
Urine (GC-MS confirmatory)	6-MAM (heroin-specific), morphine, M3G, M6G	6-MAM: 2 to 8 hours; morphine: 2 to 4 days	2,000 ng/mL (morphine confirmation)	Forensic confirmation of heroin vs. morphine/codeine
Blood	Diacetylmorphine (minutes), 6-MAM, morphine	Heroin: 3 to 5 minutes; morphine: up to 6 hours	Varies by lab; not standardized federally	Emergency/forensic; recent-use confirmation
Saliva (oral fluid)	Heroin, 6-MAM, morphine	6 hours to up to 5 days (variable)	4 ng/mL (6-MAM); 40 ng/mL (morphine)	Roadside, post-accident, custody settings
Hair follicle	Morphine, 6-MAM (incorporated into hair shaft)	Up to 90 days (scalp hair); up to 12 months (body hair)	200 pg/mg (opiates screening); 200 pg/mg (confirmation)	Pre-employment, pattern-of-use, CPS proceedings

Urine Drug Test for Heroin

Urine is the most commonly used matrix for heroin detection because it concentrates metabolites at higher levels than blood or saliva, extending the detectable window and simplifying collection logistics. Standard urine immunoassay panels screen for morphine as the primary heroin metabolite using antibody-based technology that produces a positive result when morphine concentration exceeds the established cutoff.

A positive immunoassay result is not confirmed until GC-MS confirmatory testing verifies the specific metabolites present. GC-MS analysis can identify 6-MAM alongside morphine, which is the only combination that definitively confirms heroin use rather than morphine prescription or codeine metabolism. Because 6-MAM clears urine within 2 to 8 hours, the collection timing relative to last use determines whether heroin-specific confirmation is possible.

Blood Drug Test for Heroin

Blood testing captures the narrowest detection window of any matrix. Diacetylmorphine itself is only detectable in serum for 3 to 5 minutes after administration. 6-MAM remains measurable for a slightly longer window, and free morphine persists in blood for approximately 6 hours after heroin use. Blood testing is primarily used in emergency medicine for suspected overdose confirmation or in forensic investigations where exact time-of-use reconstruction is needed, not for routine workplace or clinical monitoring.

Saliva Drug Test for Heroin

Oral fluid testing detects heroin, 6-MAM, and morphine in saliva collected via swab or passive drool device. The detection window for a saliva drug test for heroin ranges from as little as 6 hours to up to 5 days, though the confirmed-positive window for 6-MAM is shorter because saliva concentrations of opioid metabolites are lower and assay sensitivity is less standardized than urine protocols. Saliva testing is favored in post-accident and roadside enforcement settings because collection is non-invasive and observed, reducing adulteration risk.

Hair Follicle Drug Test for Heroin

Hair follicle testing incorporates drug metabolites into the keratin matrix of the hair shaft as blood circulates through hair follicles during growth. A standard scalp hair sample of 1.5 inches represents approximately 90 days of prior drug exposure, making hair drug testing for heroin the most sensitive method for identifying patterns of use rather than single instances. The hair follicle opiate screening cutoff is 200 pg/mg, with GC-MS confirmation at the same threshold identifying both 6-MAM and morphine within the hair shaft. Hair closest to the scalp represents the most recent use period, allowing segmented analysis to approximate the timeline of use.

Factors That Change Your Heroin Detection Window

The detection times in clinical reference tables represent population averages, not guarantees. Individual results vary based on biological, behavioral, and specimen-handling variables that can shift the window in either direction.

Factors That Extend Detection Time

• Chronic heavy use: Daily heroin use saturates mu-opioid receptor recycling pathways and deposits large morphine metabolite stores that extend urinary excretion beyond standard 2- to 4-day estimates.
• Liver disease or co-infection: Hepatitis C, present in an estimated 50 to 70% of people who inject drugs per SAMHSA data, impairs glucuronide conjugation and prolongs morphine’s presence in the bloodstream and urine.
• Co-administration of other opioids: Street heroin is frequently adulterated with fentanyl or contains acetylcodeine as a synthesis byproduct. Co-present opioids add separate metabolite loads that extend overall opiate panel detection and complicate metabolite attribution.
• Alkaline urine pH: Morphine excretion rate is pH-dependent. Alkaline urine (pH above 7.5) slows morphine reabsorption into the bloodstream and increases urinary excretion concentration, extending the detection window in some conditions.

Factors That Shorten Detection Time

• Single-use with low dose: A single dose of heroin in a non-tolerant individual produces morphine detectable for 24 to 48 hours in most cases, well below the upper end of population-average estimates.
• High creatinine and rapid clearance: Individuals with high baseline metabolic rate, normal liver and kidney function, and low body fat ratio clear morphine glucuronides more rapidly than average.
• Acidic urine pH: Urine pH below 5.5 increases the ionization of morphine and accelerates its renal tubular excretion, shortening the detection window by reducing reabsorption.

Why Attempts to Flush or Beat a Heroin Drug Test Do Not Work

Extreme hydration before a urine drug test dilutes creatinine concentration and reduces metabolite levels, but modern laboratory protocols flag any specimen with creatinine below 20 mg/dL as dilute. A dilute specimen triggers repeat testing or is reported as inconclusive rather than negative. Bleach, vinegar, or commercially marketed “detox drinks” do not neutralize morphine glucuronides already bound within the urine matrix at a molecular level. GC-MS confirmatory testing operates at sensitivity thresholds well above trace contamination levels, making adulteration strategies detectable rather than effective.

Heroin vs. Morphine on a Drug Test: Why They Overlap

The most common source of confusion about heroin drug test results is the metabolic overlap between heroin, morphine, and codeine on standard immunoassay opiate panels. Because heroin converts entirely to morphine, a positive opiate screen after heroin use is chemically identical to a positive screen after morphine sulfate use.

When a Positive Opiate Screen May Not Mean Heroin

Standard immunoassay panels cannot differentiate the source of morphine in urine. A positive morphine result may arise from heroin use, a legitimate morphine prescription, codeine metabolism (approximately 10% of an oral codeine dose converts to morphine), or poppy seed consumption in large quantities. Medical Review Officers (MROs) in federally regulated workplace testing are required to evaluate positive morphine screens against legitimate prescription records before releasing a confirmed positive result to an employer.

The Only Test That Proves Heroin Use: GC-MS Confirmation of 6-MAM

6-Monoacetylmorphine (6-MAM) is the single metabolite unique to heroin that cannot result from morphine, codeine, or any other legally prescribed opioid. GC-MS confirmatory testing that detects 6-MAM in urine at or above 10 ng/mL constitutes definitive proof of heroin use, regardless of any claimed prescription. The limitation is timing: 6-MAM clears urine within 2 to 8 hours post-use, so the specimen must be collected within that narrow window for heroin-specific confirmation to be possible. A negative 6-MAM result with a positive morphine result does not exclude heroin use if collection occurred after the 6-MAM clearance window.

Heroin vs. Morphine vs. Codeine: Differential Key Points

Substance	Opiate Panel Result	6-MAM Present?	Codeine Present?	Heroin Confirmed?
Heroin (within 8 hours of use)	Positive	Yes	Possibly (synthesis byproduct)	Yes
Heroin (after 8 hours)	Positive	No (cleared)	Possibly	Cannot confirm
Morphine prescription	Positive	No	No	No
Codeine prescription	Positive	No	Yes	No

Treatment for Heroin Use Disorder at Better Life Recovery

A positive heroin drug test is often the first clinical data point that leads someone toward seeking treatment for opioid use disorder (OUD). Better Life Recovery in Florham Park, New Jersey provides structured outpatient care for adults with OUD and co-occurring conditions, without requiring residential admission or on-site detoxification.

According to Sharon Cartwright, LPC, LCADC, ACS, CCS, NCC, Executive Clinical Director at Better Life Recovery: “A positive drug test is not a verdict. It is a clinical data point that opens the door to assessment and, where appropriate, to treatment. The next step after a positive result is a comprehensive evaluation, not a consequence.”

Partial Care Program for Opioid Use Disorder

Better Life Recovery’s partial care program runs Monday through Friday from 9:00 AM to 2:30 PM, providing five hours of structured daily programming for adults in early recovery from heroin or other opioid use. The program integrates individual therapy, group therapy, psychiatric services, and case management within a single daily schedule. All partial care clients complete weekly PHQ-9 and GAD-7 assessments under a measurement-based care model that tracks clinical progress in depression and anxiety symptoms across the treatment course.

Better Life Recovery accepts clients currently on Suboxone (buprenorphine/naloxone) as part of their existing medication-assisted treatment plan. The facility coordinates ongoing MAT with prescribing providers but does not perform buprenorphine inductions or administer injectable medications on-site. Clients requiring medical detoxification prior to admission are assisted with external detox placement and may return to Better Life for outpatient care once stabilized.

Intensive Outpatient Program (IOP)

The intensive outpatient program at Better Life Recovery provides lower-intensity structured treatment for individuals who have completed partial care or who present with a clinical profile that supports a less-intensive level of engagement. IOP follows the same evidence-based assessment protocols as partial care, including weekly PHQ-9 and GAD-7 measurement, and integrates the same core treatment modalities within a reduced daily schedule that allows for greater flexibility around work or family obligations.

Evidence-Based Therapies Used in Opioid Treatment

Both the partial care and IOP programs at Better Life Recovery apply evidence-based treatment frameworks directly relevant to opioid use disorder recovery.

• Dialectical Behavioral Therapy (DBT): DBT targets the emotional dysregulation, distress intolerance, and interpersonal conflict patterns that drive opioid use and relapse. Group and individual DBT components are integrated throughout the program schedule.
• Motivational Enhancement Therapy (MET): MET is applied in the substance use disorder program specifically to build intrinsic motivation for sustained abstinence and treatment engagement, particularly for clients early in their recovery process.
• Relapse Prevention: Structured relapse prevention curriculum addresses trigger identification, craving management, and coping skill development as core components of the weekly group schedule.
• Creative Art Therapy and Yoga: Supplemental modalities are incorporated within the daily programming structure as adjunct therapeutic tools alongside the primary evidence-based therapies.

Clinical Assessment at Admission

Every client admitted to Better Life Recovery undergoes a comprehensive 10-assessment intake battery that includes a complete biopsychosocial assessment, psychiatric evaluation, Columbia Suicide Severity Rating Scale, PHQ-9, GAD-7, and trauma screeners. This assessment battery determines the appropriate level of care and informs the individualized treatment plan developed by the clinical team under Sharon Cartwright’s oversight. Clients are assigned to an individual therapist during intake and receive weekly one-on-one sessions throughout the program.

To verify insurance coverage or begin the admissions process, contact Better Life Recovery’s admissions team at betterliferecovery.com/admissions.

References

1. Cone, E. J., Welch, P., Mitchell, J. M., & Paul, B. D. (1991). Forensic drug testing for opiates: I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure. Journal of Analytical Toxicology, 15(1), 1–7.
2. Moeller, K. E., Lee, K. C., & Kissack, J. C. (2008). Urine drug screening: Practical guide for clinicians. Mayo Clinic Proceedings, 83(1), 66–76.
3. Lofwall, M. R., & Walsh, S. L. (2014). A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. Substance Abuse, 35(4), 325–335.
4. Substance Abuse and Mental Health Services Administration. (2017). Clinical drug testing in primary care (Technical Assistance Publication Series 32, HHS Publication No. SMA 12-4668). SAMHSA.
5. Hadland, S. E., & Levy, S. (2016). Objective testing: Urine and other drug tests. Child and Adolescent Psychiatric Clinics of North America, 25(3), 549–565.
6. Mahone, A., Kear, T., Seavey, G., & Guthrie, K. (2023). Opioid use disorder treatment and the role of New Jersey Medicaid policy changes. Substance Abuse. PMC10826857.
7. National Institute on Drug Abuse. (2022). Heroin drug facts. U.S. Department of Health and Human Services. https://nida.nih.gov/publications/drugfacts/heroin
8. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). APA Publishing.